NYSE:ENFN - Enfusion Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.25
  • Forecasted Upside: 44.63 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$18.15
▼ -0.2 (-1.09%)

This chart shows the closing price for ENFN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enfusion Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENFN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENFN

Analyst Price Target is $26.25
▲ +44.63% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Enfusion in the last 3 months. The average price target is $26.25, with a high forecast of $27.00 and a low forecast of $26.00. The average price target represents a 44.63% upside from the last price of $18.15.

This chart shows the closing price for ENFN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Enfusion.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021William BlairInitiated CoverageOutperformLow
11/15/2021Credit Suisse GroupInitiated CoverageNeutral$26.00Low
11/15/2021Morgan StanleyInitiated CoverageEqual WeightLow
11/15/2021Stifel NicolausInitiated CoverageBuy$27.00Low
11/15/2021Bank of AmericaInitiated CoverageBuyLow
11/15/2021Piper SandlerInitiated CoverageOverweight$26.00Low
11/15/2021The Goldman Sachs GroupInitiated CoverageNeutral$26.00Low
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 0 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Very Positive

  • No very positive mentions tracked during this time.
Enfusion logo
Enfusion Inc. is a provider of cloud-based investment management software and services. Through its software, analytics and middle/back-office managed services, it creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion Inc. is based in NEW YORK.
Read More

Today's Range

Now: $18.15
Low: $17.97
High: $18.66

50 Day Range

MA: N/A

52 Week Range

Now: $18.15
Low: $17.37
High: $23.21

Volume

138,675 shs

Average Volume

548,171 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Enfusion?

The following equities research analysts have issued stock ratings on Enfusion in the last twelve months: Bank of America Co., Credit Suisse Group AG, Morgan Stanley, Piper Sandler, Stifel Nicolaus, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for ENFN.

What is the current price target for Enfusion?

4 Wall Street analysts have set twelve-month price targets for Enfusion in the last year. Their average twelve-month price target is $26.25, suggesting a possible upside of 44.6%. Stifel Nicolaus has the highest price target set, predicting ENFN will reach $27.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $26.00 for Enfusion in the next year.
View the latest price targets for ENFN.

What is the current consensus analyst rating for Enfusion?

Enfusion currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ENFN will outperform the market and that investors should add to their positions of Enfusion.
View the latest ratings for ENFN.